ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
India gives nod to cell therapy for Critical Limb Ischemia (CLI)
August 25, 2020Stempeucel®, a cell therapy for the treatment of Critical Limb Ischemia (CLI), has been approved for commercial use in India by the Drug Controller General. -
Stempeutics’ allogeneic cell therapy gets DCGI approval, Cipla to market and distribute Stempeucel
August 21, 2020Indicated for the treatment of CLI due to Buerger’s Disease and Atherosclerotic Peripheral Arterial Disease, it is the first allogeneic cell therapy product to be approved for commercial use in India. -
Stempeutics India and Novumcella Japan to work on development co-operation of Stempeucel product for
June 02, 2020As per the agreement, Novumcella will initially provide regulatory support services to Stempeutics for getting approval from Pharmaceuticals and Medical Devices Agency.
Pharma Sources Insight January 2025
